Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Disitamab Vedotin
Pfizer Australia Pty Ltd
HER2 Expressing Advanced Breast Cancer
1 trial -
Disitamab Vedotin
The First People's Hospital of Lianyungang
HER2-positive Gastric Cancer
1 trial -
Disitamab Vedotin (RC48)
The First People's Hospital of Lianyungang
Upper Tract Urothelial Carcinoma
1 trial -
combination with Disitamab Vedotin and with Tislelizumab and Capecitabine
Hospital Authority, Hong Kong
Gastric Cancer
1 trial -
disitamab vedotin
Pfizer
Urothelial Carcinoma
1 trial -
Disitamab Vedotin combined with Zimberelizumab
The First People's Hospital of Lianyungang
Biliary Carcinoma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources